Effect of pyridone agent on blood-retinal barrier in diabetic mice

Si-Qi Xiong, Hai-Bo Jiang, Hui-Zhuo Xu, Xiao-Bo Xia

Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China

Correspondence to: Xiao-Bo Xia. Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China. xbxia21@163.com

Received: 2017-02-18 Accepted: 2017-04-10

Abstract

- **AIM:** To evaluate the therapeutic effect of fluorofenidone on disrupted blood-retinal barrier in the diabetic mice and uncover its underlying mechanism.

- **METHODS:** db/db mice were randomly chosen for treatment with daily doses of fluorofenidone or placebo at 5-week-old, treatment continued until mice reach 24-week-old. Then, expression of transcriptional factor insulin gene enhancer binding protein-1 (Islet-1) and vascular endothelial growth factor (VEGF) in murine retinas were evaluated. Retinal vascular permeability was assessed by examining the level of albumin in db/db murine retinas. Furthermore, the retinal vessel tight junction was estimated by checking the level of occludin in the murine retinal tissues.

- **RESULTS:** After occurrence of diabetic retinopathy in db/db mice, expressions of transcriptional factor Islet-1 was found to be upregulated in db/db murine retinas compared with non-diabetic controls. Similar to expression pattern of Islet-1, VEGF were also demonstrated to be increased in retinas of db/db mice, which was accompanied by increased retinal vascular leakage and decreased tight junction protein level. Systemic administration of fluorofenidone repaired broken retinal vascular tight junction by restoring occludin expression in db/db retinal tissue. Consequently, retinal vascular permeability were indicated to be reduced by examining the transudative albumin level in diabetic retinal tissues. Both Islet-1 and VEGF expression were inhibited in the retinas of db/db mice after treatment with fluorofenidone.

- **CONCLUSION:** Fluorofenidone significantly protects retinal tight junction and reduces retinal vascular leakage. The phenomenon can be partially attributed to reducing overexpression of Islet-1 and VEGF in diabetic retinal tissues.

**KEYWORDS:** pyridone agent; diabetic retinopathy; blood-retinal barrier

**DOI:** 10.18240/ijo.2017.06.09


**INTRODUCTION**

Diabetic retinopathy is one of the diseases that cause vision loss in the world. Approximately 75% of all diabetic patients show clinical signs of retinopathy within 15y after onset of diabetes[1]. Diabetic macular edema arising from vascular leakage due to inner blood-retinal barrier (iBRB) damage is the major cause of loss of vision in patients with diabetic retinopathy[2]. Several cytokines have been demonstrated to participate in the pathogenesis of iBRB breakdown in diabetic patients. Growing evidence indicates that vascular endothelial growth factor (VEGF) is related to iBRB damage in diabetic retinopathy. It has been demonstrated VEGF levels dramatically upregulated in patients with diabetic macular edema and associated with vascular leakage, making it a highly important therapeutic target[3-5]. More recently, efforts with anti-VEGF therapy have produced promising results in patients with diabetic macular edema[6]. It has been confirmed that hypoxia inducible factor-1 (HIF-1) could regulate VEGF expression at transcriptional level. Treatment targeting HIF-1α could reduce the leakage of retinal blood vessels by inhibiting the expression of VEGF[7]. In addition to HIF-1α, a growing number of transcription factors, such as PPARg-coactivator-1a[8], have been shown to be involved in the regulation of VEGF expression. Figure out the regulation pathway of VEGF expression, and found more transcription factor which involved in regulating the expression of VEGF, would help us have better understanding the pathogenesis of diabetic retinopathy and providing better way to treat diabetic retinopathy.

Islet-1 is a LIM domain transcription factor[9]. The functions of Islet-1 involve in cell fate specification and embryonic development[10]. Recently, exogenous Islet-1 has been proven to possess ability to enhance proliferative, migratory and tube formation properties of the vascular endothelial cells, which
is attributed to increased secretion of VEGF[11]. Moreover, accumulated date indicate that Islet-1 gene mutation is correlated with type 2 diabetes. It could manipulate body weight and glucose homeostasis via the activation of proglucagon gene expression. Islet-1, as a transcription factor, has a role in promoting angiogenesis and associated with diabetes. However, until now, there is no research on whether endogenous Islet-1 is involved in the occurrence of diabetic retinopathy. Therefore, the current study is to investigate whether the transcription factor Islet is related to the disruption of iBRB in diabetic mice.

It has been shown that pirfenidone, as a pyridone agent, could ameliorate fibrosis in different tissues[12-13]. Oral administration of pirfenidone was approved to be safe for suppression of fibrosis in clinical trials. Fluorofenidone (AKF-PD) is an improved analog of pirfenidone. The difference in structures between fluorofenidone and pirfenidone is that the hydro- at the metaposition of the benzene ring in pirfenidone is replaced by fluoro- in fluorofenidone. Alteration of this chemical structure could result in promotion of absorption and transmission ability and increasing physiological activity. Since now, it has been demonstrated that fluorofenidone could attenuate diabetic nephropathy and kidney fibrosis in different animal models[14-15]. It is widely believed that diabetic retinopathy and nephropathy are two major microvascular complications of diabetes mellitus, which lead to blindness and end-stage renal disease. Diabetic retinopathy always find to be accompanied by diabetic nephropathy in clinic. It has also been confirmed that diabetic nephropathy was related to the severity of diabetic macular edema[16]. These findings drive us to imagine whether fluorofenidone has a therapeutic effect on diabetic retinopathy.

In order to find the answers to these questions, db/db mice were used to figure out changes of Islet-1 gene expression in murine retinal tissues during the process of diabetic retinopathy, and to find correlation between Islet-1 and diabetic retinopathy. The second purpose of our study was to evaluate the therapeutic effects of fluorofenidone on the disrupted blood-retinal barrier and to explore its underlying mechanism in diabetic mice.

**MATERIALS AND METHODS**

**Animals** C57BL/KsJ db/db male and age-matched db/m mice were obtained from Silaike (Shanghai, China), which were bred and maintained in a pathogen-free environment with a 12-hour light/dark cycle. The experimental animals were composed of following groups: normal control group (db/m mice, n=16), negative control group (1% CMC-Na was used to treat db/db mice, n=16) and treatment group (db/db mice treated by oral gavage at dose of 500 mg/(kg • d) of fluorofenidone, n=16). Treatment started at the age of 5wk with an end point at 24-week old. Body weight of mice was measured.

**Analysis of Blood Glucose and Serum Lipids** Following a 12-hour overnight fast, blood from the tail vein was collected. Blood glucose meter was used to measure blood glucose levels in mice (LifeScan, Milpitas, CA, USA). Meanwhile, automatic analyzer model 7170 (Hitachi Co., Ltd., Japan) was adopted to examine serum levels of triglyceride and cholesterol.

**Determination of Disruption of Blood-retinal Barrier** In order to analyze the extent of damage of the blood-retinal barrier in db/db mice, the level of albumin leaking from retinal vessels was evaluated. Once deeply anesthetized, the chest of the mice was opened followed by insertion of a catheter into the left ventricle with a small incision on the right atrium. Phosphate buffer saline was infused. Consequently, mice were sacrificed and retina was isolated, extravascular level of albumin in murine retina was assessed by using the Western blot technique.

**Western Blot** Total protein of murine retinas were collected and resolved on sodium dodecyl sulfate (SDS)-polyacrylamide gel, then it was transferred onto a nitrocellulose membrane and incubated with anti-Islet-1 (Abcam, UK), anti-VEGF (Abcam, UK), anti-Albumin(Abcam, UK), anti-occludin (Abcam, UK) and anti-β-actin antibodies (Sigma, USA). Membranes were incubated with peroxidase-conjugated secondary antibodies and developed using the ECL system.

**Statistical Analysis** All the data were expressed as mean±SEM and processed by SPSS20.0 statistical package. One-way analysis of variance followed by the LSD test were utilized to assess significant differences. P<0.05 would be considered to be statistically significant.

**RESULTS**

**Clinical Characteristics of the Mice After Fluorofenidone Treatment** Serum lipid together with blood glucose and body weight were monitored in db/db mice before and after fluorofenidone treatment. Body weights (db/db vs db/m: 50.97±2.95 vs 33.02±0.44 g, P<0.05) and blood glucose concentrations of db/mice (db/db vs db/m: 41.11±3.61 vs 9.51±0.72 mmol/L, P<0.05) were dramatically increased compared with db/m mice. Similarly, we also found serum concentrations of cholesterol (db/db vs littermates: 3.08±0.62 vs 2.04±0.21 mmol/L, P<0.05) and triglycerides (db/db vs littermates: 1.04±0.15 vs 0.41±0.05 mmol/L, P<0.05) were upregulated in db/db mice when compared with db/m mice. Conversely, the difference between fluorofenidone-treated db/db and placebo-treated db/db mice was insignificant. Treatment with fluorofenidone did not affect serum levels of triglycerides (fluorofenidone vs db/db: 1.00±0.11 vs 1.04±0.15 mmol/L, P>0.05), cholesterol (fluorofenidone vs db/db: 43.06±0.13 vs 3.08±0.62 mmol/L, P>0.05), glucose (fluorofenidone vs db/db: 41.17±2.78 vs 41.11±3.61 mmol/L, P>0.05) compared with placebo-treated mice. Fluorofenidone did not change body weight of the mice (fluorofenidone vs db/db: 47.75±4.83
In summary, with progression of diabetes, db/db mice manifested as increased body weight and elevated level of blood glucose and serum lipid.

**Downregulation of Retinal Islet-1 Expression in the Retinas of db/db Mice by Fluorofenidone**

To figure out the relationship between Islet-1 and diabetic retinopathy, Islet-1 level in the retinas of db/db mice was evaluated at age 24wk. Diabetic retinopathy has been occurring in the retinal tissues at this time. We found that expression of Islet-1 in db/db murine retina was significantly increased compared with normal control (P<0.05, Figure 2). This indicates that the occurrence of diabetic retinopathy can induce the expression of Islet-1, we infer that there is a positive correlation between the expression of Islet-1 and diabetic retinopathy and Islet-1 may play a potential role in this process. We also found, compared with placebo-treated db/db mice, systematic administration of fluorofenidone suppressed the expression of Islet-1 in the db/db retinas (P<0.05, Figure 2). It has been proven that the level of transcriptional factor Islet-1 in the retinas of mice was assayed by Western blot. Islet-1 expression in the db/db murine retinas were dramatically increased compared with normal control mice. Systematic administration of fluorofenidone almost completely attenuated upregulation which was induced by diabetes to normal level (Figure 2).

**Effect of Fluorofenidone on Vascular Endothelial Growth Factor Expression in the Retinas of db/db Mice**

Overexpression of VEGF has been demonstrated in diabetic retinopathy, which result in disruption of blood-retinal barrier and vascular leakage. Be consistent with it, we detected an increased level of VEGF in db/db retinas with high glucose compared with normal control mice (P<0.05, Figure 3). Then, effects of fluorofenidone on retinal VEGF expression in db/db mice was evaluated. Compared with placebo-treated db/db mice, VEGF expression was dramatically decreased in the retinas of db/db mice which was systematically administrated with fluorofenidone (P<0.05, Figure 3). It has been proven that...
that Islet-1 could promote the angiogenesis by increasing the expression of VEGF. This indicates that Islet directly or indirectly participate in the regulation of VEGF expression. We observed inhibition of the expression of Islet-1 in retinal tissues by fluorofenidone, which may consequentially downregulate expression of VEGF on transcriptional level in the retina of diabetic mice.

**Effect of Fluorofenidone on Blood-retina Barrier in db/db Mice** In order to examine the therapeutic efficacy of fluorofenidone on the blood-retinal barrier, we detected the level of albumin in murine retinal tissues. As shown in Figure 4, the level of albumin was significantly increased in the retinas of db/db mice compared with that of normal control ($P<0.05$). Systematic administration of fluorofenidone significantly decreased extravascular leakage of albumin in db/db mice (Figure 4, $P<0.05$). To figure out whether this phenomenon was related to alteration of the tight junction protein expression, we assessed the level of occludin in the retina of db/db mice. It demonstrated that the expression of occludin downregulated in db/db mice compared with non-diabetic littersmates (Figure 5, $P<0.05$). Fluorofenidone treatment almost completely restored retinal occludin expression in db/db mice (Figure 5, $P<0.05$).

**DISCUSSION**

Significant upregulation of Islet-1 expression were found in the retinas of db/db mice. Islet-1 transcriptional activity play important roles in tissue specification and correlate with the activity of the insulin and glucagon genes$^{[17-20]}$. It has been shown that Islet-1 could promote postnatal angiogenesis and vasculogenesis, which is attributed to increased secretion of VEGF$^{[11]}$. In current study, along with elevated expression
of Islet-1, the level of VEGF also increased significantly in db/db mice. Previous reports have demonstrated that VEGF could improve vascular permeability in diabetic patients and correlated with the diabetic macular edema[21]. In this study, expression of Islet-1 was significantly increased in parallel with elevated VEGF levels, vascular leakage and tight junction damage in the retinas of db/db mice. These findings suggest that Islet-1 may participate in diabetes-induced VEGF expression and iBRB breakdown.

Our findings showed that fluorofenidone significantly reversed retinal vascular leakage. To further unveil whether fluorofenidone has direct effects on the blood retinal barrier, we evaluated the effect of fluorofenidone on retinal tight junction. Our findings indicated that fluorofenidone attenuated the downregulation of tight junction protein-occludin in the retinas of db/db mice. Several studies have demonstrated that VEGF-mediated disruption of endothelial transmembrane tight-junction proteins is contributed to the breakdown of iBRB in diabetic retinopathy[22]. In accord with previous study, downregulation of tight junction protein is associated with decrease of VEGF levels in the retinal tissues after administration of fluorofenidone. We show here that protein expression of Islet-1 were suppressed by treatment with fluorofenidone. Downregulation expression of Islet-1 could concomitant attenuation of VEGF levels in retinals of db/db mice. These findings indicate an important role of Islet-1 in retinal vascular leakage through regulation of VEGF expression. Moreover, some other unknown factors implicated in iBRB breakdown may also be regulated by Islet-1. Inhibition of Islet-1 by systematically administration of fluorofenidone may suppress retinal vascular leakage through decreasing Islet-1 regulated other downstream genes besides VEGF. Further study is necessary to elucidated it.

In summary, our study suggested that Islet-1 expression is upregulated in association with VEGF expression in the retinas of db/db mice, which is attributed to retinal vascular leakage and tight junction disruption. Florofenidone could reverse retinal tight junction and reduce retinal vascular leakage in db/db mice. The therapeutic efficacy of fluorofenidone on blood-retinal barrier is at least in part mediated by the inhibition of VEGF expression via attenuation of Islet-1 levels in diabetic retinal tissues.

ACKNOWLEDGEMENTS
We thank Dr. Li-Jian Tao and Dr. Xuan Xiong for providing db/db mice with fluorofenidone treatment.

Foundations: Supported by National Natural Science Foundation of China (No.81000388); Health and Family Planning Commission of Hunan Province (No.132015-016); Natural Science Foundation of Hunan Province (No.12JJ3120).

Conflicts of Interest: Xiong SQ, None; Jiang HB, None; Xu HZ, None; Xia XB, None.

REFERENCES
15 Qin J, Xie YY, Huang L, Yuan QJ, Mei WJ, Yuan XN, Hu GY, Cheng GJ, Tao LJ, Peng ZZ. Fluorofenidone inhibits nicotinamide


